Deep-pocketed investors have adopted a bullish approach towards Pfizer PFE, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PFE usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 26 extraordinary options activities for Pfizer. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 57% leaning bullish and 42% bearish. Among these notable options, 14 are puts, totaling $805,001, and 12 are calls, amounting to $1,049,799.
What's The Price Target?
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $20.0 to $80.0 for Pfizer over the last 3 months.
Insights into Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Pfizer's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Pfizer's significant trades, within a strike price range of $20.0 to $80.0, over the past month.
Pfizer Option Activity Analysis: Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| PFE | CALL | SWEEP | BULLISH | 02/02/24 | $29.50 | $249.4K | 1.6K | 14.0K |
| PFE | CALL | TRADE | BEARISH | 04/19/24 | $31.00 | $232.4K | 11.2K | 4.3K |
| PFE | PUT | TRADE | BULLISH | 06/20/25 | $25.00 | $202.0K | 10.1K | 1.0K |
| PFE | CALL | SWEEP | BEARISH | 01/26/24 | $20.00 | $150.4K | 29 | 306 |
| PFE | PUT | SWEEP | BULLISH | 06/21/24 | $30.00 | $142.2K | 25.0K | 491 |
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Following our analysis of the options activities associated with Pfizer, we pivot to a closer look at the company's own performance.
Present Market Standing of Pfizer
- Currently trading with a volume of 24,036,795, the PFE's price is up by 0.35%, now at $28.53.
- RSI readings suggest the stock is currently is currently neutral between overbought and oversold.
- Anticipated earnings release is in 6 days.
Expert Opinions on Pfizer
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $38.5.
- An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45.
- An analyst from TD Cowen has revised its rating downward to Market Perform, adjusting the price target to $32.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pfizer options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
